Source comparison
Thymosin Alpha-1 vs VIP: Research Peptide Comparison
Primary Mechanism TLR2 agonist; upregulates dendritic cell function and T-cell proliferation through MyD88 signaling VPAC1/VPAC2 receptor agonist; raises cAMP to inhibit NF-kB and suppress pro-inflammatory cytokines Fundamentally non-overlapping pathways. One
This comparison does not assign a generated winner or score.
- Primary Mechanism
- TLR2 agonist; upregulates dendritic cell function and T-cell proliferation through MyD88 signaling
- VPAC1/VPAC2 receptor agonist; raises cAMP to inhibit NF-kB and suppress pro-inflammatory cytokines
- Fundamentally non-overlapping pathways. One amplifies adaptive immunity, the other dampens innate inflammation
- Amino Acid Length
- 28 amino acids (acetylated N-terminus)
- 28 amino acids (unmodified)
- Identical length but distinct sequences; Tα1's acetylation confers greater stability
- Half-Life (Circulating)
- 2–3 hours (subcutaneous)
- 1–2 minutes (IV/IP)
- VIP requires continuous infusion or frequent dosing; Tα1 allows twice-weekly protocols
- Storage Stability (Reconstituted)
- 28 days at 2–8°C in bacteriostatic water (>95% potency)
- 14 days at 2–8°C (85–90% potency retained)
- Tα1 is more forgiving in multi-week protocols; VIP degrades faster due to peptidase sensitivity
- Primary Research Use
- Immune deficiency models, vaccine adjuvant studies, chronic viral infection research
- Inflammation resolution, autoimmune modeling, pulmonary/vascular smooth muscle studies
- Selection should be dictated by study endpoint. Not peptide popularity or supplier recommendation
- Documented Dosing (Preclinical)
- 1.6 mg subcutaneous twice weekly (murine/human equivalent dose scaled)
- 25–100 nmol/kg IV or IP (dosing frequency: every 4–6 hours for sustained effect)
- Tα1 dosing is straightforward; VIP requires continuous delivery or multiple daily administrations